Patients with a breast cancer, lung cancer, leukemia, lymphoma, GI malignancies, GU cancer, and other malignancies will be entered on therapeutic and scientific protocols developed by the Cancer and Leukemia Group B (CALGB). During the grant period, Dartmouth will continue to make significant contributions to the scientific and administrative activities of the CALGB. Several new investigators have been recruited and Dartmouth has instituted disease specific multidisciplinary teams to enhance our ability to translate new findings in the laboratory into clinical trials. Dartmouth has developed a clinical research base which will lead to a number of new directions. The emphasis of these new directions will be to study the interactions of the traditional multidisciplinary therapeutic modalities of surgery, radiation and chemotherapy with immunomodulation (in non-small cell lung cancer, GI cancer, GU cancer, breast cancer, leukemia and lymphoma), chemomodulation (GI and GU cancer), or interaction with inhibitors of clotting factors (small cell lung cancer). One of the major programs will be the Phase 1/11 testing of bispecific antibodies with the aim of using this technology in minimal residual disease. New initiatives will be to broaden the base for recruitment of patients to clinical trials through an initiative entitled """"""""Clinical Trials in a Rural Population"""""""", as well as expand other affiliate programs. With these initiatives it is expected that accrual will rise to a minimum goal of 200 during the first year of this application.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dartmouth College
Schools of Medicine
United States
Zip Code
Lawson, David H; Lee, Sandra; Zhao, Fengmin et al. (2015) Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Compl J Clin Oncol 33:4066-76
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Wang, Xiaofeng; Owzar, Kouros; Gupta, Pankaj et al. (2014) Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol 78:1005-13
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98

Showing the most recent 10 out of 108 publications